Buprenorphine diversion and misuse in outpatient practice

Journal of Addiction Medicine

Volumn 8, Issue 5, 2014, Pages 327-332

  Lofwall, Michelle R ^a   Martin, Judith ^b   Tierney, Matt ^c   Fatséas, Mélina ^d,e   Auriacombe, Marc ^d,e   Lintzeris, Nicholas ^f,g,h  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CITY AND COUNTY OF SAN FRANCISCO   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^g Centre for Population Health   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adherence; Buprenorphine; Buprenorphine naloxone; Diversion; Misuse; Outpatient opioid addiction treatment; Stepped care

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPRAZOLAM; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; HEPATITIS C ANTIBODY; OXYCODONE; NARCOTIC ANTAGONIST;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABUSE; ANALGESIA; ANTIBODY TITER; ARM FRACTURE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BENZODIAZEPINE DEPENDENCE; CANNABIS USE; CASE REPORT; CHILD ABUSE; COCAINE DEPENDENCE; CONFERENCE PAPER; DOPING; DRUG ABUSE PATTERN; DRUG DOSE REDUCTION; DRUG MISUSE; DRUG MONITORING; DRUG OVERDOSE; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MEDICAL HISTORY; METHAMPHETAMINE DEPENDENCE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTPATIENT; PATIENT COUNSELING; PATIENT HISTORY OF ORTHOPEDIC SURGERY; POSTOPERATIVE PAIN; PRESCRIPTION DRUG DIVERSION; SMOKING; VERBAL HOSTILITY; WITHDRAWAL SYNDROME; AMBULATORY CARE; OPIOID-RELATED DISORDERS;

ADULT; AMBULATORY CARE; BUPRENORPHINE; FEMALE; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION DRUG MISUSE;

EID: 84921850559     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000029     Document Type: Conference Paper

References (19)

1. Aboltins CA, Allen P, Daffy JR. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust 2005;182:427.
2. Auriacombe M, Franques P, Daulouède J, et al. Les modalites de mise a disposition d'un traitement de substitution par buprenorphine influencentelles la reponse generale au traitement? Resultats preliminaires d'une etude. Courrier des Addictions 2002;4:104-106.
3. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346-350.
4. Fatseas M, Auriacombe M. Principes de la thérapeutique et des prises en charge en addictologie. In: Lejoyeux M, ed. Abrégé d'Addictologie. Paris: Masson, 2009:62-69.
5. Fatseas M, Lavie E, Denis C, et al. Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiatedependent patients. J Subst Abuse Treat 2009;37:407-411.
6. Hersh D, Little SL, Gleghorn A. Integrating buprenorphine treatment into a public healthcare system: the San Francisco Department of Public Health's office-based Buprenorphine Pilot Program. J Psychoactive Drugs 2011;43:136-145.
7. Holliday S, Magin P, Dunbabin J, et al. An evaluation of the prescription of opioids for chronic nonmalignant pain by Australian general practitioners. Pain Med 2013;14:62-74.
8. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011;5: 254-263.
9. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Intern Med J 2009;39:676-681.
10. Lofwall MR, Walsh SL. Clinical challenges in managing buprenorphine diversion. J Addict Med 2010;4:243.
11. Lofwall MR, Wunsch MJ, Nuzzo PA, et al. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat 2011;41:321-329.
12. Mee-Lee D, Shulman GD. The ASAM placement criteria and matching patients to treatment. In:Ries RK, Fiellin DA, Miller SC, eds. Principles of Addiction Medicine. 4th ed. Philadelphia: LippincottWilliams & Wilkins, 2009:chap 27.
13. O'Brien CP. Review. Evidence-based treatments of addiction. Philos Trans R Soc Lond B Biol Sci 2008;363:3277-3286.
14. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008a;97:105-113.
15. Roux P, Villes V, Bry D, et al. Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict Behav 2008b;33:1625-1629.
16. Royal Australasian College of Physicians. Prescription opioid policy: improving management of chronic non-malignant pain and prevention of problems associated with prescription opioid use. 2009. Available at: http://www.ranzcp.org/Files/ranzcp-attachments/Resources/Submissions/CNMP-pdf.aspx. Accessed January 2013.
17. Shand FL, Campbell G, Hall W, et al. Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Med J Aust 2013;198: 80-81.
18. Sobell MB, Sobell LC. Stepped care as a heuristic approach to the treatment of alcohol problems. J Consult Clin Psychol 2000;68: 573-579.
19. Swendsen J, Le Moal M. Individual vulnerability to addiction. Ann N Y Acad Sci 2011;1216:73-85.